business

Novartis

Analysts Barclays highlight Novartis' (NVS) challenges with upcoming patent expirations despite promising outlook for remibrutinib

Novartis is optimistic about its experimental multiple sclerosis drug remibrutinib, projecting over $4 billion in peak annual sales, despite recent concerns from analysts about its efficacy compared to competitors. This situation underscores the company's challenges as it navigates upcoming patent expirations for key products and seeks to solidify its growth strategy.